Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
Acadia Pharmaceuticals (ACAD) stock gains as an appeal court hears oral arguments regarding a patent dispute related to its lead drug, Nuplazid. Read more here.
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.
ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $31.95, a
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Acadia Pharmaceuticals (ACAD) just stacked two key clinical milestones: a fresh USPTO Notice of Allowance extending potential trofinetide protection to 2041 and Phase 2 RADIANT data guiding remlifanserin into Phase 3 for Alzheimer’s disease psychosis. Despite the fresh patent progress and Phase 2 readout, Acadia Pharmaceuticals’ share price has retreated, with a 30-day share price return down 28.23% and year-to-date share price return down 23.51%, while the 5-year total shareholder return of...
Detailed price information for Aldeyra Therapeu (ALDX-Q) from The Globe and Mail including charting and trades.
SAN DIEGO, September 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled "Methods and Compositions for Treatment of Rett Syndrome." The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrati
Acadia Pharmaceuticals has seen its share price fall sharply over the past month, and that pullback is pushing investors to ask whether the current valuation still lines up with what the business is earning today. With the stock under pressure and expectations around its drug pipeline shifting, the key issue is how much of those earnings are already reflected in the price. The share price is down 29.0% over the past month. That puts fresh focus on whether recent weakness has moved Acadia...
Tipranks Press Release.
Detailed price information for Kyverna Therapeutics Inc (KYTX-Q) from The Globe and Mail including charting and trades.
Acadia Pharmaceuticals' (ACAD) favorable risk-reward remains intact despite remlifanserin narrowly m
Acadia hopes to become one of the first companies to secure approval for a therapy specifically indicated for ADP.
ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $32.37, a
Acadia's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation.
ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs. In its market note, the investment firm reiterated its sell recommendation and $17 price target on the stock after missing its primary endpoint in its phase 2 study […]
This is the newest page. Registered accounts read further back.